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Introduction

Schizophrenia
Schizophrenia is a severe,and often debilitating, psychiatric illness that routinely is first observed in late adolescence/early adulthood [1, 2] . Clinical features vary among individuals, and they encompass aheterogenousgroup of symptoms and signs that can be subgrouped into three major domains: positive (delusions, hallucinations), negative (apathy, amotivation, blunted affect etc.), and cognitive (impaired memory, attention, executive functions, etc.). The etiopathogenesis of schizophrenia remains elusive despite a half century of systematic research [3] , although it was soon after the introduction of antipsychotics in the early 1950's that dopamine receptors and its blockade was first posited as the mechanism of action of antipsychotics. It remains to this point that all drugs effective in treatment of schizophrenia target dopamine receptors, anddopamine receptors continue to be targets in new drug development research [4] . In this review we summarise the evidence for targeting dopamine receptors in schizophrenia, specifically focusing on drugs in Phase III trials.
Dopamine hypothesis of schizophrenia
While other theories have been forwarded, the dopamine hypothesis has remained central to any discussion regarding the pathogenesis and treatment of schizophrenia. Over the last few decades, the hypothesis has evolved from general dopaminergic hyperactivity [5, 6] to regional dopamine differences (subcortical hyperdopaminergia and cortical hypodopaminergia) [7] to dopamine dysregulation as the final common pathway [8] . The initial model hypothesized general hyperactivity of the dopaminergic system, predominantly based on pharmacological studies indicating dopamine neurotransmission as the target of antipsychotic action [9] [10] [11] [12] . Later, this model was revised to incorporate the advances arising from imaging and animal studies [13] [14] [15] ,with the recent revision positioning dopamine dysregulation as the final common pathway, implicating a complex interplay of factors that may play a contributory role [8] .
Implication for clinical symptoms
Although chlorpromazine's antipsychotic properties were discovered in the early 1950s [16] , it took several more decades to establish that it was the dopamine blocking properties of these drugs, and more specifically D 2 blockade, that accounted for their antipsychotic effects [17, 18] .
With this information in hand, it was possible to move from the low potency conventional antipsychotics like chlorpromazine, with their heterogeneous receptor binding profiles, to the development of highly selective D 2 antagonists, such as haloperidol and pimozide. Clozapine's unique pharmacological profile (e.g. low affinity for the D 2 receptor), in combination with evidence regarding its superior efficacy in treatment resistant schizophrenia, fostered the search for other 'atypical' antipsychotics and non-dopaminergic mechanisms (e.g. serotonergic, glutamatergic and α-adrenergic) that might account for their different clinical profile [19] [20] [21] .
While different lines of investigation were pursued (e.g. selective serotonin 5-HT 2 antagonism), current thinking has come full circle and reiterated the position that at least some degree of D 2 receptor blockade is necessary for antipsychotic activity [22] . Accordingly, the dopamine receptor continues to represent a key target in schizophrenia drug discovery, and the next section reviews related investigational drugs in phase III trials. 
Downstream effects of dopamine receptor stimulation: dopamine receptor signaling
Dopamine receptors constitute 7-transmembrane domain receptors and belong to a large family of G-protein coupled receptors. Binding of dopamine to receptor activates G-protein, which induces a sequence of intracellular events [28] [29] [30] . Though G-protein coupled signalling is regarded as the common mechanism of dopamine receptors, studies have implicated G-protein independent signalling events as well [31, 32] .Depending on receptor subtype, stimulation of Gprotein can either stimulate or inhibit cAMP production; D 1 class stimulate, while D 2 class inhibit CAMP production ( Figure 2) . The activity of G protein mediated signaling is modulated by proteins termed arrestins and regulators of G protein signaling (RGS), proteins which play an important role in the desensitization/internalization of receptors [23, [33] [34] [35] [36] . There is growing appreciation that these downstream signalling mechanisms, especially the Akt/GSK-3 signalling cascade, play an important role in psychiatric disorders and, as a result, are targets for novel psychotropic drugs [37, 38] . 
Rationale for targeting dopamine receptors in schizophrenia 3.1 Neuroimaging and postmortem evidence
Studies have examined dopamine receptors in schizophrenia using in vivo imaging (Positron Emission Tomography, PET; Single Photon Emission Computed Tomography, SPECT) as well as postmortem samples. Postsynaptic D 2/3 receptor density has been extensively examined in both post-mortem and in vivo studies, with meta-analyses reporting small elevations in receptor density; however, it is also acknowledged that these results can be confounded by previous medication use [39] [40] [41] [42] . Amphetamine-induced dopamine release and depletion paradigm studies have also demonstrated increased striatal dopamine release [43] [44] [45] and elevated baseline dopamine activity [46] [47] [48] [49] . Most of the aforementioned studies examined striatal dopamine receptors using raclopride, a predominantly D 2 selective ligand. Recently, the role of the D 3 receptor in schizophrenia has been investigated using 
Dopamine's role beyond psychosis: negative and cognitive symptoms
The initial dopamine hypothesis posited schizophrenia to be a disorder of general dopaminergic hyperactivity [5, 6] ,addressing theantipsychotic action of what were then termed 'neuroleptics' [60] , but not the negative and cognitive symptom domains. Over the years attention has increasingly focused on these other features and, not surprisingly, has also examined putative role of dopamine. Evidence favouring dopamine's involvement can be summarised as follows: 
Drugs Targeting Dopamine Receptors in Phase III trials
Dopamine receptor antagonists
• BL-1020
BL-1020 is a γ-aminobutyric acid (GABA)-enhanced molecule with combined dopamine antagonism and GABA agonism. In a recently completed phase II, randomized trial, 363
patients received BL-1020 in one of two doses (10, 20 mg), placebo, or risperidone (2-6 mg).
BL-1020 was significantly better than placebo for treatment of positive symptoms, and superior to both placebo and risperidone for treatment of cognitive deficits [95] . However, the manufacturer BiolineRx, a biopharmaceutical development company, discontinued the randomized clinical trials, blonanserin proved superior to placebo, with equal efficacy to haloperidol and risperidone, for positive symptoms, in addition to superiority versus haloperidol in terms of negative symptoms [99] [100] [101] [102] . In one open-label trial, blonanserin had moderate effect on cognitive symptoms in first episode, but not chronic,patients with schizophrenia [103] .
• Zicronapine Zicronapine's pharmacological profile includes D 1 , D 2 and 5HT 2A receptor antagonist properties. In twophase II trials, multiple doses of zicronapine (3, 5, 7, 10 mg) were compared to placebo and olanzapine; zicronapine 7 and 10mg were more efficacious compared to placebo, and comparable with olanzapine [104] . A phase III clinical trial is complete but results are pending (Table 1 ).
Dopamine receptor agonist/partial agonists
• Cariprazine
Cariprazine is a D 3 preferential D 2 /D 3 receptor partial agonist [105] currently being evaluated for relapse prevention in schizophrenia (Table 1) . It also has affinity for 5HT 2B and 5HT 1A receptors. In a multicentre, double-blind, randomized trial 73 participants received cariprazine in one of three doses (1.5, 3, 4.5 mg), risperidone 4 mg, or placebo. Cariprazine was well tolerated, significantly improved PANSS as well as Clinical Global ImpressionSeverity (CGI-S) scores versus placebo, and was comparable to risperidone [106] . The halflife of its metabolite, didesmethyl-cariprazine is longer than that of cariprazine, which may allow for the development of a once-weekly oral formulation [107] . Two short-term phase III trials involving schizophrenia were recently completed. In one, 617 subjects were randomized to cariprazine 3 or 6 mg/day, aripiprazole 10mg/day or placebo. In the second, 446 subjects were randomized to cariprazine 3-6 mg/day, cariprazine 6-9 mg/day or placebo.
Both studies reported significant improvement in PANSS scores withcariprazine treatment compared to placebo. Common adverse events reported includedakathisia, insomnia, headache, restlessness and extrapyramidal symptoms [108] .A new drug application has been filed [96] .
• Bromocriptine Bromocriptine is a dopamine receptor agonist presently usedin gynecology for treatment of hyperprolactinemia [109] . Recently it has also been examined in psychiatry, in this case forantipsychotic-induced hyperprolactinemia.In one open-label study, bromocriptinesignificantly decreased hyperprolactinemia secondary to antipsychotic treatment with no worsening of psychotic or extrapyramidal symptoms (EPS) [110] . Asecond open-label trial for the same indication is currently registered, although the status is not known (Table 1 ).
• Bifeprunox
Bifeprunox is a partial agonist at D 2 and 5-HT 1A receptors. It also has high affinity for D 3 and D 4 receptors, although it is relatively devoid of 5HT 2A , α 1 , α 2 , muscarinic, and histaminergic receptor binding. In a phase II double-blind, placebo-controlled study, 589 patients were administered bifeprunox in one of three doses (5, 10, 20 mg), placebo or risperidone 6 mg. Bifeprunox 20 mg produced significant reductions in PANSS scores compared to placebo, but did not match risperidone [111] . Later trials of bifeprunox were terminated, and the drug was rejected by US FDA.
Other mechanisms (non-receptor mediated dopaminergic action)
• Lisdexamfetamine
Lisdexamfetamine is a prodrug of amphetamine, a drug indicated in the treatment of [112] . A phase III trial was registered but withdrawn for non-safety related business prioritization reasons.
Existing drug in alternate formulation
• Inhaled loxapine
Loxapine, an antipsychotic used worldwide, is well established in the treatment of schizophrenia. It manifests D 2 antagonistic activity in line with other first generation antipsychotics, in addition to 5HT 2A antagonism although not of the magnitude assigned to 'atypicality'. Intramuscular loxapine is used in both the acute and maintenance treatment of schizophrenia. In a recent study loxapine was delivered by inhalation using a novel Staccato delivery system to people with schizophrenia and agitation;a total of 344 individuals were recruited in a phase III, randomized, double-blind, placebo-controlled, parallel-group study comparing inhaled loxapine (5 or 10 mg) versus placebo. Both doses significantly reduced agitation versus placebo, as assessed by the Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) 2 h after first dose [113] .The effect size for the PANSS-EC at 2 h was 0.45 for the 5 mg dose and 0.60 for the 10 mg dose, arguing for the 10 mg dose [114] .
Common adverse events included sedation, dysgeusia and dizziness. Serious adverse effects, namely wheezing/bronchospasm, was reported in three participants, and neck dystonia/oculogyric crisis in one participant.
Conclusion
_____________________________________________________________________________
A half century after it was implicated in the pathophysiology of schizophrenia and the action of antipsychotics, dopamine continues to garner considerable attention in terms of drug development. However, the landscape has changed considerably, in part because of developments in our understanding regarding dopamine but also because of changes in how we conceptualize schizophrenia. The former is reflected in drugs like blonanserin and zicronapine, which focus beyond the notion of highly selective D 2 blockade, albeit for different reasons.
Interest in the D 3 receptor is largely premised on its possible involvement in psychosis [115] , whereas the D 1 receptor is of interest for its putative role in other domains such as negative symptoms and cognition. To this last point, it is fair to say that enthusiasm for developing better antipsychotic medication remains, but is being overshadowed by current interest in improving these other features. This is clearly reflected in Table 1, where 5 of the 8 drugs under investigation (blonanserin, BL-1020, cariprazine, zicronapine, lisdexamfetamine) identify either negative symptoms or cognition as a treatment target. Such a transition is very much in line with the field, which has increasingly shifted its focus from clinical to functional recovery [116] .
Drugs that block dopamine and the D 2 receptor have proven to be at least reasonably effective antipsychotic drugs, but they fall considerably short in terms of efficacy in treating the other features of schizophrenia. Notably, this holds true for the newer antipsychotics as well, including clozapine [117, 118] .
Expert opinion
_____________________________________________________________________________
It is interesting to track the direction schizophrenia drug development has taken from the standpoint of what has evolved clinically. At the time high potency conventional antipsychotics were taking over the market, psychiatry really only conceptualized schizophrenia as a disorder of psychosis. It was these individuals who filled institutions, and the discovery of neuroleptics was critical to the deinstitutionalization process that had begun post-World War II [119] . It was not until the 1980's that the notion of two symptom domains (positive and negative) gathered momentum and, notably, at that time it was postulated that negative symptoms were representative of underlying morphological changes not particularly amenable to pharmacological treatment.
Clozapine's reintroduction in the early 1990's in many countries, including the United States [120] , generated a series of new drugs that collectively claimed 'atypical' status, generating a level of excitement and optimism that the field had not witnessed in decades. Indeed, a kind of therapeutic nihilism had grown through the 1980's as it became apparent that selective D 2 antagonists were not going to be the panacea hoped for based on existing theory. In this context, and given how unique clozapine seemed both clinically and pharmacologically, it is not surprising that expectations were high for what these new drugs might do. Earlier evidence that they led to improvement in both negative and cognitive symptoms was rapidly embraced, but over the next decade tempered considerably with later reports acknowledging that benefits in these domains were modest at best [117, 118] . At the same time, the initial notion that these drugs effected greater and broader efficacy was linked in particular to their higher serotonin 5-HT 2 versus D 2 binding profile [121] , a model so popular that by the late 1990's the need for D 2 blockade was even being called into question [122] .
The fallout of these events has led us to an interesting spot. It turns out that we have not built better antipsychotics with the exception of clozapine, and its clinical superiority seems confined to a specific subpopulation, that is treatment resistant schizophrenia (TRS). Moreover, we are left not knowing why it is superior to all other antipsychotics in this regard. Two widely held hypothetical models to explain atypicality have focused on serotonin-dopamine [121] and transient D 2 binding [123] , both of which are unable to account for clozapine's greater efficacy in TRS. Atypicals mirroring clozapine on one or even both levels simply haven't delivered a similar clinical profile.
In getting to this point though, we have learned much more about schizophrenia. It is no longer conceptualized as a disorder of only psychosis; in fact, in many ways psychosis has taken a back seat to other symptom domains. More specifically, the enthusiasm to fully tap the benefits of these new and purportedly better medications led to increased expectations regarding functional recovery, and reports were soon implicating the negative and cognitive symptoms as the rate limiting features of the illness [124] . Unfortunately, as this message was crystallizing it was also becoming increasingly apparent that the drugs generating this research were falling short of initial expectations.
In looking at the drugs in Table 1 , we can see pieces of this story. The search for better antipsychotic drugs continues, but remains built upon D 2 binding. As an aside, the search for therapeutic agents effecting their response through other mechanisms continues; for example, there is considerable interest in glutamatergic drugs [125] , although recent excitement generated regarding an mGlu2/3 receptor agonist [126] has since been tempered by follow-up data [127] .
What is most noteworthy from the standpoint of dopamine is the search for its role in these other symptoms, in combination with the notion that this will come through increasing dopaminergic activity. This categorically flies in the face of the old axiom that drugs acting in this fashion (e.g. L-dopa) are contraindicated in individuals with psychosis [128] . Additionally, it is fair to say that dopamine does not have the same foothold with respect to these other symptoms that is holds regarding positive symptoms. In that sense, the field is much more open to the possibility that systems beyond dopamine may play important roles in these other domains.
What is less clear is whether we can pharmacologically impact negative symptoms and cognitive deficits in a way that translates to meaningful clinical improvement, regardless of mechanism(s) of action. In addition, and particularly relevant to drugs enhancing dopamine, is the clinical reality that they must be administered in the context of concomitant D 2 antagonism. We already see this scenario played out in the form of the partial dopamine agonist, aripripazole, which because of its uniqueness has been identified as the first 'third generation' antipsychotic [129] .
At least to date, evidence has not been forthcoming that it has produced gains in these other features of schizophrenia that would set it apart from other atypicals. In going down this road, what we are beginning to see, however, is a shift away from the development of single drugs that attempt to do all things. Instead, as reflected in this review, drugs are being developed that may well be specific to a single domain, setting the stage for polypharmacy, with choice of agent and combinations shaped by the specific clinical profile of the particular individual -a step closer to personalized medicine. 
Table1: List of investigational drugs targeting dopamine receptors in Schizophrenia
